Alexandra June Gordon
A5085016627- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Sepsis Diagnosis and Treatment
- Emergency and Acute Care Studies
- COVID-19 epidemiological studies
- Viral gastroenteritis research and epidemiology
- Simulation-Based Education in Healthcare
- Trauma and Emergency Care Studies
- Myofascial pain diagnosis and treatment
- Influenza Virus Research Studies
- COVID-19 and healthcare impacts
- Ultrasound in Clinical Applications
- Venous Thromboembolism Diagnosis and Management
- Respiratory viral infections research
- Mechanical Circulatory Support Devices
- Botulinum Toxin and Related Neurological Disorders
- Clinical Reasoning and Diagnostic Skills
- Autopsy Techniques and Outcomes
- Advanced oxidation water treatment
- Biomedical and Engineering Education
- Bipolar Disorder and Treatment
- Hereditary Neurological Disorders
- Advanced Photocatalysis Techniques
- Nuclear reactor physics and engineering
Cerner (United States)
2024
Stanford University
2019-2023
Stanford Medicine
2020-2023
Stanford Health Care
2023
Loughborough University
2023
University of Pittsburgh
2023
Icahn School of Medicine at Mount Sinai
2019-2022
Palo Alto University
2021-2022
Albert Einstein College of Medicine
2022
Cwm Taf University Health Board
2021
A comprehensive understanding of the benefits COVID-19 vaccination requires consideration disease attenuation, determined as whether people who develop despite have lower severity than unvaccinated people.
To characterize the clinical severity of covid-19 associated with alpha, delta, and omicron SARS-CoV-2 variants among adults admitted to hospital compare effectiveness mRNA vaccines prevent admissions related each variant.
Data are not complete for all characteristics in the table; denominators
Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first vaccines approved use under an Emergency Use Authorization (EUA) in United States (1-3). In evaluation 24 hospitals 14 states,* effectiveness of partial or full vaccination† with Pfizer-BioNTech Moderna against COVID-19-associated hospitalization was assessed among adults years. Among 417 hospitalized (including 187 case-patients 230 controls), median age...
Real-world evaluations have demonstrated high effectiveness of vaccines against COVID-19-associated hospitalizations (1-4) measured shortly after vaccination; longer follow-up is needed to assess durability protection. In an evaluation at 21 hospitals in 18 states, the duration mRNA vaccine (Pfizer-BioNTech or Moderna) (VE) was assessed among adults aged ≥18 years. Among 3,089 hospitalized (including 1,194 COVID-19 case-patients and 1,895 non-COVID-19 control-patients), median age 59 years,...
As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination coverage increases in the United States, there is a need to understand real-world effectiveness against disease 2019 (COVID-19) and among people at increased risk for poor outcomes.In multicenter case-control analysis of US adults hospitalized March 11-May 5, 2021, we evaluated vaccine prevent COVID-19 hospitalizations by comparing odds prior with messenger RNA (mRNA) (Pfizer-BioNTech or Moderna) between cases...
ABSTRACT Background As SARS-CoV-2 vaccination coverage increases in the United States (US), there is a need to understand real-world effectiveness against severe Covid-19 and among people at increased risk for poor outcomes. Methods In multicenter case-control analysis of US adults hospitalized March 11 - May 5, 2021, we evaluated vaccine prevent hospitalizations by comparing odds prior with an mRNA (Pfizer-BioNTech or Moderna) between cases hospital-based controls who tested negative...
The SARS-CoV-2 Omicron variant (B.1.1.529 or BA.1) became predominant in the United States by late December 2021 (1). BA.1 has since been replaced emerging lineages BA.2 (including BA.2.12.1) March 2022, followed BA.4 and BA.5, which have accounted for a majority of infections June 2022 Data on effectiveness monovalent mRNA COVID-19 vaccines against BA.4/BA.5-associated hospitalizations are limited, their interpretation is complicated waning vaccine-induced immunity (2-5). Further, with...
COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 vaccine, which targets Omicron JN.1 JN.1-derived sublineages. Interim effectiveness of vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits September 2024-January 2025 among adults ≥18 years in one...
To characterize the clinical severity of COVID-19 caused by Omicron, Delta, and Alpha SARS-CoV-2 variants among hospitalized adults to compare effectiveness mRNA vaccines prevent hospitalizations each variant.A case-control study 11,690 adults.Twenty-one hospitals across United States.This included 5728 cases with 5962 controls without COVID-19. Cases were classified into variant groups based on viral whole genome sequencing, if sequencing did not reveal a lineage, predominant circulating at...
To determine whether implementation of an Emergency Critical Care Program (ECCP) is associated with improved survival and early downgrade critically ill medical patients in the emergency department (ED).Single-center, retrospective cohort study using ED-visit data between 2015 2019.Tertiary academic center.Adult presenting to ED a critical care admission order within 12 hours arrival.Dedicated bedside for ICU by ED-based intensivist following initial resuscitation team.Primary outcomes were...
Objectives: To compare the effectiveness of a primary COVID-19 vaccine series plus booster dose with alone for prevention Omicron variant hospitalization. Design: Multicenter observational case-control study using test-negative design to evaluate (VE). Setting: Twenty-one hospitals in United States (US). Participants: 3,181 adults hospitalized an acute respiratory illness between December 26, 2021 and April 30, 2022, period SARS-CoV-2 (BA.1, BA.2) predominance. Participants included 1,572...
Background: Sodium zirconium cyclosilicate (SZC) and patiromer (PAT) are potassium binders that differ by exchange ion, sodium, calcium, respectively. There is limited data on whether using sodium could impact the risks of hospitalizations for heart failure (HHF) or severe edema in patients with hyperkalemia. Objectives: To assess occurrence rates pre-specified major encounters potentially related to electrolyte-/fluid-related imbalances (including HHF, edema) among new users PAT SZC...
With the rising number of female physicians, there will be more children than ever born in residency, and current system is inadequate to handle this increase new resident parents. Residency stressful rigorous isolation, let alone when pregnant or with a child. Policies that ease these transitions are generally either insufficient do not exist. Therefore, we created comprehensive return-to-work policy for parents piloted its implementation. Our aims to: 1) establish clear, shared...
Objectives Estimating mortality risk in hospitalised SARS-CoV-2+ patients may help with choosing level of care and discussions patients. The Coronavirus Clinical Characterisation Consortium Mortality Score (4C Score) is a promising COVID-19 model. We examined the association factors 30-day hospitalised, full-code investigated discrimination calibration 4C Score. This was retrospective cohort study within RECOVER (REgistry suspected EmeRgency care) network. Setting 99 emergency departments...
Vaccine effectiveness (VE) against COVID-19 hospitalization was evaluated among immunocompetent adults (≥18 years) during March-August 2021 using a case-control design. Among 1669 hospitalized cases (11% fully vaccinated) and 1950 RT-PCR-negative controls (54% vaccinated), VE 96% (95% confidence interval [CI], 93%-98%) patients with no chronic medical conditions 83% CI, 76%-88%) ≥ 3 categories of conditions. similar between those aged 18-64 years versus ≥65 (P > .05). severe very high...
Background . Adults in the United States (US) began receiving adenovirus vector coronavirus disease 2019 (COVID-19) vaccine, Ad26.COV2.S (Johnson & Johnson [Janssen]), February 2021. We evaluated vaccine effectiveness (VE) against COVID-19 hospitalization and high severity during first 10 months of its use. Methods In a multicenter case-control analysis US adults (≥18 years) hospitalized 11 March to 15 December 2021, we estimated VE susceptibility (VEs), comparing odds prior vaccination with...
Coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE) studies are increasingly reporting relative VE (rVE) comparing a primary series plus booster doses with only. Interpretation of rVE differs from traditional measuring absolute (aVE) regimen against an unvaccinated referent group. We estimated aVE and COVID-19 hospitalization in primary-series first-booster recipients vaccines.Booster-eligible immunocompetent adults hospitalized at 21 medical centers the United States during...
Coronary microembolization is one of the main causes "no-reflow" phenomenon, which commonly occurs after reperfusion an occluded coronary artery. Given its high incidence and fact that it has been proven to be independent predictor cardiac morbidity mortality, there imperative need study underlying mechanisms pathophysiology. Large animal models are essential perform translational studies. Currently no model recapitulates a clinical scenario thrombogenic microembolism with preceding...
A disappointing number of new therapies for pulmonary hypertension (PH) have been successfully translated to the clinic. Adeno-associated viral (AAV) gene therapy has potential treat underlying pathology PH, but challenge remains in efficient and safe delivery. The aims this study were (1) test efficacy endobronchial aerosolization delivery AAV1-mediated sarcoplasmic/endoplasmic reticulum Ca
Objectives Point‐of‐care ultrasound (POCUS) detects the pulmonary manifestations of COVID‐19 and may predict patient outcomes. Methods We conducted a prospective cohort study at four hospitals from March 2020 to January 2021 evaluate lung POCUS clinical outcomes COVID‐19. Inclusion criteria included adult patients hospitalized for who received with 12‐zone protocol. Each image was interpreted by two reviewers blinded Our primary outcome need intensive care unit (ICU) admission versus no ICU...
Studies have found that prolonged boarding time for intensive care unit (ICU) patients in the emergency department (ED) is associated with higher in-hospital mortality. However, these studies introduced selection bias by excluding ICU admission orders who were downgraded and never arrived ICU. Consequently, they may overestimate mortality ED boarders.This was a retrospective cohort study at single center covering period from August 14, 2015 to 13, 2019. Adult medical least 6 hours of...